Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. today announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100*

Today, the US Food and Drug Administration converted the approval process for Leqembi indicated for the treatment of adult patients with Alzheimer's disease, is on traditional approval after a confirmatory study verified clinical benefit.

NS Pharma, Inc. announced today the U.S. Food & Drug Administration has granted Rare Pediatric Disease Designation to NS-089/NCNP-02 (brogidirsen) an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.

South Rampart Pharma, Inc. a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the China National Intellectual

Asieris Pharmaceuticals a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related

BioArctic AB's partner Eisai announced today that the U.S. Food and Drug Administration, FDA, has approved the supplemental Biologics License Application, sBLA, supporting the traditional

Novavax, Inc.a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has been granted full Marketing Authorization by the European Commission

Pheon Therapeutics a leading Antibody-Drug Conjugate specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces an exclusive licence agreement

Ascentage Pharma announced today that the company's core product Orebatinib has obtained clinical trial approval from the Center for Drug Evaluation of the National Medical Products

Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for the company’s Biologics License Application for zolbetuximab